Loading...
Oncodesign SA
ALONC.PA•EURONEXT
Healthcare
Biotechnology
€14.42
€0.00(0.00%)
Oncodesign SA (ALONC.PA) AI-Powered Stock Analysis
See how Oncodesign SA scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerOncodesign SA (ALONC.PA) Stock Overall Grade
Oncodesign SA’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
C+
Normal
Grade Breakdown by Metric
See how each financial and market factor contributes to Oncodesign SA's overall stock rating.
Forecast
C+Score
50/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
CScore
42/100Sector Comparison
B+Score
75/100Industry Comparison
B+Score
75/100S&P 500 Benchmark
AScore
85/100Analyst Consensus
C+Score
50/100Oncodesign SA (ALONC.PA) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 50/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (42/100, C) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (85/100, A), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Oncodesign SA stock grade, including financials, comparisons, and forecasts.